Skip to main
TIL

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc is positioned favorably due to its innovative focus on developing a pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies, particularly with its CoStAR platform that leverages genetically engineered TILs targeting various solid tumors. The potential for significant therapeutic advancements in oncology, as demonstrated in recent developments related to PD-(L)1 × VEGF activity, suggests the company could benefit from a broader positive sentiment within the biopharmaceutical sector. Furthermore, there is an opportunity for valuation upside as Instil Bio's technology platform could expand into additional indications, enhancing its overall growth trajectory in the competitive cancer treatment landscape.

Bears say

Instil Bio Inc. faces a negative outlook primarily due to the discontinuation of AXN-2510, which was a key value driver, necessitating a complete reassessment of the company's financial thesis. Bearish sentiments are fueled by concerns over the perceived similarity of overall survival (OS) curves pre- and post-discontinuation, coupled with risks of delays and unfavorable clinical data in ongoing and future assessments of its pipeline candidates. Additionally, the potential for medium- to long-term dilution poses further financial risks, while current share performance is described as stagnant until clearer strategic direction is established.

Instil Bio (TIL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.